OncoSec Medical (ONCSQ) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Nab Paclitaxel, Tavokinogene Telseplasmid, Immunopulse, Gemcitabine Plus Carboplatin | Triple Negative Breast Cancer | Phase II | Unknown | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | Jun 13, 2018 | ― |
| Pembrolizumab, Tavokinogene Telseplasmid, Immunopulse | Stage Iii/Iv Melanoma | Phase II | Unknown | Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment | Apr 24, 2017 | ― |
| It-Pil12-Ep | Er-Negative Pr-Negative Her2-Negative Breast Cancer | Phase I | Completed | Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC | Aug 18, 2015 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Head And Neck Squamous Cell Carcinoma | Phase II | Terminated | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) | Jan 19, 2015 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Cutaneous T Cell Lymphomas (Ctcl), Mycosis Fungoides (Mf) | Phase II | Terminated | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma | Apr 15, 2012 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Melanoma | Phase II | Completed | Trial of pIL-12 Electroporation Malignant Melanoma | Dec 21, 2011 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Merkel Cell Carcinoma | Phase II | Completed | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer | Sep 23, 2011 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Nab Paclitaxel, Tavokinogene Telseplasmid, Immunopulse, Gemcitabine Plus Carboplatin | Phase II | Triple Negative Breast Cancer | Unknown | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | Jun 13, 2018 | ― |
| Pembrolizumab, Tavokinogene Telseplasmid, Immunopulse | Phase II | Stage Iii/Iv Melanoma | Unknown | Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment | Apr 24, 2017 | ― |
| It-Pil12-Ep | Phase I | Er-Negative Pr-Negative Her2-Negative Breast Cancer | Completed | Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC | Aug 18, 2015 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Phase II | Head And Neck Squamous Cell Carcinoma | Terminated | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) | Jan 19, 2015 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Phase II | Cutaneous T Cell Lymphomas (Ctcl), Mycosis Fungoides (Mf) | Terminated | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma | Apr 15, 2012 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Phase II | Melanoma | Completed | Trial of pIL-12 Electroporation Malignant Melanoma | Dec 21, 2011 | ― |
| Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms) | Phase II | Merkel Cell Carcinoma | Completed | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer | Sep 23, 2011 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oncosec Medical Incorporated (ONCSQ) have in its pipeline
OncoSec Medical ONCSQ is currently developing the following drugs: Pembrolizumab, Nab Paclitaxel, Tavokinogene Telseplasmid, Immunopulse, Gemcitabine Plus Carboplatin, Pembrolizumab, Tavokinogene Telseplasmid, Immunopulse, It-Pil12-Ep, Tavokinogene Telseplasmid (Tavo), Oncosec Medical System (Oms). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
